Pulmonary Hypertension in Patients Eligible for Transcatheter Mitral Valve Repair: Prognostic Impact and Clinical Implications
- 24 Downloads
Purpose of review
Transcatheter edge-to-edge mitral valve repair (TMVr) has been increasingly used in the treatment of patients with severe symptomatic mitral regurgitation who are at high or prohibitive risk for surgical intervention. Pre-existing pulmonary hypertension is known to pertain worse prognosis for patients who are undergoing surgical intervention. The aim of this review is to discuss the current literature on the effects of pulmonary hypertension on the transcatheter edge-to-edge mitral valve repair outcomes.
Large registry data in patients undergoing TMVr for treatment of severe mitral regurgitation reveal a significant negative impact of baseline pulmonary hypertension on post-procedural outcomes.
Pulmonary hypertension is associated with increased mortality and heart failure readmissions in patients undergoing TMVr using MitraClip. Further prospective studies are needed to determine whether earlier intervention will improve clinical outcomes.
KeywordsMitral regurgitation Transcutaneous mitral valve repair MitraClip Transcatheter mitral valve repair Pulmonary hypertension
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, et al. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J. 2011;32(6):751–9.CrossRefGoogle Scholar
- 3.Ghoreishi M, Evans CF, DeFilippi CR, Hobbs G, Young CA, Griffith BP, et al. Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg. 2011;142(6):1439–52.CrossRefGoogle Scholar
- 4.•• Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group. JACC Cardiovasc Imaging. 2015;8(1):83–99. This is an excellent review of pulmonary hypertension in valvular disease.PubMedGoogle Scholar
- 5.Patel H, Desai M, Tuzcu EM, Griffin B, Kapadia S. Pulmonary hypertension in mitral regurgitation. J Am Heart Assoc. 2014;3(4).Google Scholar
- 6.Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, Segovia-Cubero J, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39(15):1255–64.CrossRefGoogle Scholar
- 7.Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89.CrossRefGoogle Scholar
- 11.Yang H, Davidson WR Jr, Chambers CE, Pae WE, Sun B, Campbell DB, et al. Preoperative pulmonary hypertension is associated with postoperative left ventricular dysfunction in chronic organic mitral regurgitation: an echocardiographic and hemodynamic study. J Am Soc Echocardiogr. 2006;19(8):1051–5.CrossRefGoogle Scholar
- 13.• Mentias A, Patel K, Patel H, Gillinov AM, Sabik JF, Mihaljevic T, et al. Effect of pulmonary vascular pressures on long-term outcome in patients with primary mitral regurgitation. J Am Coll Cardiol. 2016;67(25):2952–61. This is one of the largest surgical series evaluating the prognostic significant of preoperative PH in low-risk patients.CrossRefGoogle Scholar
- 18.Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–61.CrossRefGoogle Scholar
- 32.Tigges E, Blankenberg S, von Bardeleben RS, Zurn C, Bekeredjian R, Ouarrak T, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2018;20(3):585–94.CrossRefGoogle Scholar
- 33.Ahmed A, Akintoye E, Adegbala O, Yassin A, Subahi A, Bangura L, et al. In-hospital outcomes of transcatheter mitral valve repair with Mitraclip in patients with pulmonary hypertension: Insights from the National Inpatient Sample. Catheter Cardiovasc Interv. 2018.Google Scholar
- 34.•• Al-Bawardy R, Vemulapalli S, Thourani V, Mack M, Ben Assa E, Palacios I, Inglessis I, Sakhuja R, Ben-Assa E, Passeri J, Dal-Bianco J, Yucel E, Melnitchouk S, Vlahakes G, Jassar A, Dai D, Elmariah S. Effects of pulmonary hypertension on transcatheter mitral valve repair outcomes: an analysis of the STS/ACC TVT registry. JAMA Cardiology. 2019 (In press). Currently the largest registry data evaluating the implication of PH in patients undergoing MitraClip therapy.Google Scholar
- 35.Asch F. Heart failure and secondary mitral regurgitation: echocardiographic outcomes from the COAPT trial. [Presented at ACC 2019].Google Scholar